The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts.
 
Anna Capasso
No Relationships to Disclose
 
Julie Lang
No Relationships to Disclose
 
Todd M. Pitts
No Relationships to Disclose
 
Paul Francoeur
No Relationships to Disclose
 
Sarah Lindsey Davis
No Relationships to Disclose
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Merck; Merrimack
Other Relationship - Immune Design
 
Stacey M Bagby
No Relationships to Disclose
 
John J. Tentler
No Relationships to Disclose
 
Anthony d Piscopio
Employment - OnKure
Stock and Other Ownership Interests - OnKure
 
Jennifer Robinson Diamond
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Casi Pharmaceuticals; Genentech/Roche (Inst); MedImmune (Inst); Millennium (Inst); OncoMed (Inst); Scripps Hospital (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takeda; Takeda
 
Roberta Pelanda
No Relationships to Disclose
 
S. Gail Eckhardt
Consulting or Advisory Role - CASI Pharmaceuticals; Champions Biotechnology; Kyowa Hakko Kirin; Lilly/ImClone; OnKure; Pfizer; Sanofi; Suvica; Taiho Pharmaceutical
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); cleave biosciences (Inst); Genentech (Inst); OncoMed (Inst); Rexahn Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Genentech; Kyowa Hakko Kirin; Lilly/ImClone; Sanofi; Taiho Pharmaceutical